Steno-2 demonstrated that intensive multifactorial risk factor intervention targeting glycaemia, blood pressure, lipids, and lifestyle simultaneously reduces all-cause mortality by 46% and cardiovascular events by 59% over 13.3 years in type 2 diabetes with microalbuminuria, providing the defining evidence for comprehensive cardiovascular risk management in high-risk type 2 diabetes.
Browsing: All
UKPDS 38 demonstrated that tight blood pressure control targeting below 150/85 mmHg reduces stroke by 44%, diabetes-related endpoints by 24%, and microvascular complications by 37% in hypertensive type 2 diabetes over 8.4 years, establishing blood pressure control as a therapeutic target of at least equal macrovascular importance to glycaemic management.
UKPDS 34 demonstrated that metformin reduces diabetes-related endpoints, death, and all-cause mortality by 32–42% in overweight patients with newly diagnosed type 2 diabetes, with superior cardiovascular outcomes compared with sulphonylurea or insulin, establishing metformin as the preferred first-line pharmacological therapy for type 2 diabetes for the subsequent three decades.
UKPDS 33 established that intensive blood-glucose control with sulphonylurea or insulin reduces microvascular complications by 25% in newly diagnosed type 2 diabetes over 10 years with a 0.9% HbA1c differential, confirming the glucose hypothesis for type 2 diabetes microvascular disease and forming the foundational evidence for tight glycaemic management from diagnosis.
The EDIC study demonstrated that 6.5 years of intensive glycaemic therapy during the DCCT reduced cardiovascular events by 42–57% over 17 years of follow-up despite subsequent HbA1c convergence between groups, establishing the concept of metabolic memory and providing foundational evidence that early intensive glycaemic control produces durable cardiovascular protection extending decades beyond the intervention period.
The Diabetes Control and Complications Trial demonstrated that intensive insulin therapy targeting near-normal blood glucose reduced the risk of developing retinopathy by 76% in primary prevention and slowed progression by 54% in secondary intervention, while also substantially reducing nephropathy and neuropathy, establishing the foundational evidence for tight glycaemic control in type 1 diabetes.
A man convinced his wife’s hormones are the problem. A woman whose husband answers every question for her. Two composite vignettes from one fictional clinic afternoon.
A bride who needs answers before Saturday. A sixteen-year-old boy with mild numbers and a mother carrying more hope than he is. Two composite vignettes from one fictional clinic morning.
A Wednesday morning. A man with a calculator and an invented ratio. A man who has been quietly afraid for eleven years. Two composite vignettes from one fictional clinic.
A woman who arrived with a folder convinced her thyroid was destroyed. A man who did not know he had diabetes. Two patients on one fictional Tuesday morning. Composite vignettes.